标题
Adverse Events Associated With PCSK9 Inhibitors: A Real-World Experience
作者
关键词
-
出版物
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-07-28
DOI
10.1002/cpt.1193
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort
- (2018) Michael Saborowski et al. Cardiology Journal
- No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data
- (2017) Philip D Harvey et al. EUROPEAN HEART JOURNAL
- 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
- (2017) Ulf Landmesser et al. EUROPEAN HEART JOURNAL
- Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres
- (2017) Monika Kohli et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical experience
- (2017) Annette M.H. Galema-Boers et al. Journal of Clinical Lipidology
- Safety of Very Low Low-Density Lipoprotein Cholesterol Levels With Alirocumab
- (2017) Jennifer G. Robinson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
- (2017) Robert P Giugliano et al. LANCET
- Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
- (2017) Joshua Choi et al. Lipids in Health and Disease
- Cognitive Function in a Randomized Trial of Evolocumab
- (2017) Robert P. Giugliano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
- (2017) Kausik K. Ray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Risk of Adverse Neurocognitive Outcomes With Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors
- (2017) Abdur Rahman Khan et al. Circulation-Cardiovascular Quality and Outcomes
- Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
- (2017) Aris Karatasakis et al. Journal of the American Heart Association
- Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers
- (2017) Alejandro Arrieta et al. JAMA Cardiology
- Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials
- (2016) Peter H. Jones et al. AMERICAN JOURNAL OF CARDIOLOGY
- Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
- (2016) Charalambos Vlachopoulos et al. ATHEROSCLEROSIS
- PCSK9 inhibition as an emerging lipid lowering therapy: Unanswered questions
- (2016) Lοukianos S. Rallidis et al. Hellenic Journal of Cardiology
- Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials
- (2015) Xin-Lin Zhang et al. BMC Medicine
- Effects of Evolocumab on Vitamin E and Steroid Hormone LevelsNovelty and Significance
- (2015) Dirk J. Blom et al. CIRCULATION RESEARCH
- The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
- (2015) Michael J. Lipinski et al. EUROPEAN HEART JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
- (2015) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway
- (2013) A.L. Catapano et al. ATHEROSCLEROSIS
- Immunotoxicity of monoclonal antibodies
- (2010) Jacques Descotes mAbs
- Beyond the Randomized Clinical Trial
- (2008) Brahmajee K. Nallamothu et al. CIRCULATION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started